(Total Views: 159)
Posted On: 12/12/2017 10:07:21 AM
Post# of 72447
"In spite of OM incidence rates ranging as high as 100 percent in HNC [head and neck cancer], there currently are no FDA-approved drugs for the prevention and treatment of OM in these types of cancer patients receiving chemoradiation."
And this is why the 60% OM rate in the control group for our clinical trial is suspect. Other clinical trials reported a 75% OM rate in the control group.
Brilacidin reduced the incidence of severe OM by FIFTY PERCENT -- about 37%, instead of about 75%. That's enough to warrant FDA approval.
And this is why the 60% OM rate in the control group for our clinical trial is suspect. Other clinical trials reported a 75% OM rate in the control group.
Brilacidin reduced the incidence of severe OM by FIFTY PERCENT -- about 37%, instead of about 75%. That's enough to warrant FDA approval.
(6)
(0)
